Topline  Presentation Points

  • What Is the Best Second Line Treatment for Hodgkin Lymphoma? 
    • Highest CURE rate and LOWEST toxicity 
    • Unlikely to be one-size-fits-all 
    • Should depend upon front-line treatment, baseline risk factors
  • Predictors of treatment sensitivity
  • Early markers of long-term success
  • Three new drugs change the Hodgkin lymphoma landscape: brentuximab vedotin, nivolumab, and pembrolizumab
  • Improving cure rates in the second-line setting and what accounts for improvement 
    • Pre-transplant PET – most consistent prognostic factor for relapsed/refractory HL 
    • Risk adapted and PET-adapted salvage therapy for rel/ref HL at MSKCC 
    • Metabolic tumor volume improves the predictive power of pre-ASCT PET 
  • Post-transplant brentuximab vedotin maintenance 
    • AETHERA: Phase III study evaluating post-transplant maintenance BV for higher risk patients 
  • personalizing second-line therapy 
    • Should baseline risk factors guide therapy? 
      • Is pre-transplant PET the optimal endpoint? 
  • Are there reliable predictors of treatment sensitivity? 
    • Metabolic tumor volume improves the predictive power of pre-ASCT PET 
  • Can we predict long-term success? 
    • ctDNA may improve predictive power of interim PET 
    • Can 9p24.1 amplification identify the best candidates for PD-1 blockade?